Condiciones de SaludEl dolor de espalda, o dolor en la espalda, se refiere a malestar o dolor en los músculos, huesos o nervios de la espalda, que va de leve a severo. Es una de las razones más comunes de ausencias laborales y visitas al médico. Los dolores de espalda pueden ser agudos (a corto plazo, frecuentemente debido a una lesión o tensión) o crónicos (que duran más de tres meses). El dolor puede localizarse en la parte baja de la espalda, la parte media de la espalda, o la parte alta de la espalda, y a veces irradiar hacia las piernas (como en la ciática).
Las causas van desde tensión muscular y desequilibrios posturales hasta problemas más graves como discos herniados o afecciones espinales. Si bien la mayoría de los dolores de espalda se resuelven con autocuidado, el dolor crónico o severo puede requerir evaluación médica para identificar problemas estructurales subyacentes.
Tipos:
Dolor en la parte baja de la espalda (lumbago): El tipo más común, frecuentemente debido a tensión o problemas de disco.
Dolor en la parte alta o media de la espalda: Menos común, frecuentemente relacionado con la postura o desequilibrios musculares.
Dolor de espalda relacionado con la ciática: Irradia desde la parte baja de la espalda hacia las piernas debido a la compresión nerviosa.
Dolor de espalda agudo: Dura unos pocos días a semanas, típicamente por tensión o lesión.
Dolor de espalda crónico: Dura más de tres meses, puede derivar de problemas estructurales o enfermedad subyacente.
Causas Comunes (Factores de Riesgo):
Tensión muscular o de ligamentos: Uso excesivo, levantamiento de objetos pesados o movimientos inadecuados.
Mala postura: Períodos prolongados de estar sentado, especialmente con ergonomía inadecuada.
Discos abultados o herniados: Comprimen los nervios espinales, causando dolor y entumecimiento.
Artritis: La osteoartritis puede afectar la columna vertebral, reduciendo el espacio alrededor de la médula espinal.
Osteoporosis: Debilita los huesos, provocando fracturas en las vértebras.
Estilo de vida sedentario: Los músculos del núcleo débiles no logran sostener la columna vertebral.
Obesidad: Añade estrés a los músculos de la espalda y la columna vertebral.
Estrés y tensión emocional: Pueden causar rigidez muscular y malestar en la espalda.
Causas Más Graves (Complicaciones):
Discos herniados con compresión nerviosa: Pueden provocar debilidad, entumecimiento o ciática.
Estenosis espinal: Estrechamiento del canal espinal, que causa dolor nervioso.
Discapacidad crónica: Limita la movilidad y la calidad de vida.
Depresión y ansiedad: Comunes en quienes padecen dolor crónico.
Anomalías estructurales: Escoliosis, enfermedad degenerativa del disco.
Cuándo Consultar a un Médico o Especialista (Ortopedista, Neurólogo):
Dolor de espalda que dura más de unas pocas semanas
Dolor severo que no mejora con el reposo
Dolor que irradia hacia las piernas (ciática) o acompañado de entumecimiento o debilidad
Dificultad para controlar la función de la vejiga o el intestino (posible emergencia por compresión nerviosa)
Antecedentes de cáncer, osteoporosis, o traumatismo reciente con dolor de espalda
Pérdida de peso inexplicable junto con dolor de espalda
ALA is a plant-derived short-chain omega-3 fatty acid that reduces corneal epithelial damage and inflammation in DED animal models when applied topically. As the primary omega-3 in flaxseed oil, oral ALA has shown clinical benefit in observational studies. Short-chain precursor status requires enzymatic conversion to EPA/DHA, making it less potent than long-chain forms for oral use.
Omega-3s in algal oil, particularly DHA and EPA, may ease dry eye symptoms by slowing tear evaporation and reducing ocular surface inflammation. Clinical reviews support omega-3 supplementation for dry eye relief, with effects attributed to DHA's anti-inflammatory properties in the lacrimal gland and ocular surface. Benefits have been noted for contact lens wearers and screen users.
A prospective quasi-experimental clinical study (n=60 patients, 120 eyes, Beijing Tongren Hospital) found oral astaxanthin 6 mg twice daily for 30 days significantly improved OSDI, TBUT, corneal fluorescein staining, and meibomian gland function in mild-to-moderate DED. It crosses the blood-retinal barrier and inhibits HMGB1, TNF-α, and IL-1β in corneal epithelial cells.
Bilberry (Vaccinium myrtillus) anthocyanins have been studied in clinical RCTs for dry eye, with a 3-month pilot RCT (n=24, 600 mg bilberry + fish oil) showing improvements in OSDI, NITBUT, tear secretion, and meibomian gland openings. A separate RCT found 160 mg bilberry extract for 4 weeks improved tear volume by Schirmer test. Anti-inflammatory and vasoprotective anthocyanins reduce oxidative stress on the ocular surface.
EPA and DHA supplementation from marine sources reduces dry eye disease (DED) symptoms by dampening ocular surface inflammation. Multiple RCTs have shown improvements in tear breakup time, osmolarity, and Ocular Surface Disease Index (OSDI) scores. Calamari oil provides the same DHA/EPA active components studied in these trials.
Capsanthin from Capsicum annuum was tested in a rat benzalkonium chloride-induced dry eye model, demonstrating significant improvements in tear break-up time, Schirmer scores, intraocular pressure, and corneal inflammation. Antioxidant enzyme levels were also improved.
Chondroitin sulfate is used both as an active lubricant and as a vehicle in ophthalmic formulations for dry eye disease (DED). Multiple clinical trials have evaluated CS-containing eye drops, demonstrating improvements in goblet cell density, tear break-up time, OSDI scores, and corneal staining. A phase III multicenter RCT and a phase IV double-blind RCT have both assessed CS-based solutions against comparators, showing non-inferior or superior outcomes.
Chrysanthemum has both traditional TCM use and emerging scientific evidence for dry eye conditions. A 2025/2026 Inflammopharmacology study showed wild chrysanthemum essential oil improved tear production, corneal integrity, and goblet cell density in a dry eye mouse model via NF-κB pathway suppression. A clinical RCT using a chrysanthemum-containing botanical formula improved dry eye symptoms in 360 participants.
Omega-3 fatty acids from cod liver oil reduce ocular surface inflammation implicated in dry eye disease. Multiple RCTs and meta-analyses have examined oral omega-3 supplementation for dry eye, with evidence of improvements in tear break-up time and ocular surface staining. However, a large recent trial (DREAM study) found no significant benefit over placebo.
CoQ10 has been studied for dry eye disease through clinical trials showing topical CoQ10 with crosslinked hyaluronic acid improved DED outcomes, reduced all cytokine levels, and elevated total antioxidant status. Histopathological analyses confirmed CoQ10 protects lacrimal gland structure and function from oxidative damage. It is one of ten evidence-supported DED nutrients per a 2024 Frontiers in Pharmacology systematic review.
An 8-week prospective randomized double-blind placebo-controlled RCT (n=155 DED patients) using curcumin 200 mg + lutein + zeaxanthin + vitamin D3 met both primary DED endpoints (Schirmer and OSDI, p<0.001). Curcumin reduces pro-inflammatory cytokines in corneal epithelial cells, inhibits NF-κB, and reduces oxidative stress and MMP-9 in ocular surface models.
DHA is the other principal long-chain omega-3 fatty acid co-evaluated with EPA in dry eye RCTs. It is incorporated into lacrimal gland cell membrane phospholipids, modulating inflammatory signaling. Clinical meta-analyses confirm combined EPA+DHA supplements improve TBUT, Schirmer test, and OSDI scores in DED patients.
DHA and EPA modulate ocular surface inflammation through eicosanoid pathways, shifting the balance toward anti-inflammatory mediators. DHA plays an active role in organizing the lacrimal lipid film, reducing tear evaporation and improving Meibomian gland lipid secretion. Phase 3 clinical trials have been conducted for EPA+DHA supplementation in dry eye disease.
EPA-containing omega-3 supplementation has been evaluated in multiple RCTs for dry eye disease (DED). A meta-analysis of 19 RCTs (n=4,246 patients) found significant improvements in tear break-up time, Schirmer's test, corneal staining, and osmolarity, with EPA percentage a significant predictor of symptom improvement.
EPA is a primary long-chain omega-3 fatty acid studied in dry eye disease across multiple RCTs and meta-analyses. Higher EPA percentages within omega-3 formulations are associated with greater reductions in DED symptom scores. EPA suppresses pro-inflammatory cytokines and modulates the ocular surface inflammatory cascade as a precursor to anti-inflammatory prostaglandins.
Fish oil EPA and DHA modulate tear film quality through anti-inflammatory and specialized pro-resolving mediator (resolvin, protectin) pathways. Multiple RCTs and the large DREAM extension study have evaluated omega-3 for dry eye disease. A 2025 RCT in Sjögren's syndrome patients found significantly lower dry eye symptom scores with omega-3 versus placebo.
Flaxseed oil, rich in ALA omega-3, has been studied for dry eye through a prospective observational study (n=200) reporting 85% symptom relief at 2 months with oral flaxseed oil. Topical flaxseed oil artificial tears showed benefit in a randomized controlled trial. Preclinical studies confirmed topical ALA from flaxseed reduced corneal inflammation.
GLA is an omega-6 fatty acid and precursor to prostaglandin E1 (PGE1), a key molecule for tear production and lacrimal gland secretion. Multiple RCTs using GLA combined with EPA/DHA showed improved tear film lipid layer stability, reduced tear evaporation, and reduced DED inflammation. Sources include borage and evening primrose oil.
In an animal model of dry eye disease, goji berry extract (GBE) at multiple doses significantly improved Schirmer's test scores and tear break-up time within one week and reduced keratoconjunctival staining severity. The berry's antioxidant and anti-inflammatory constituents are proposed mechanisms. Human clinical data are not yet available, but preclinical evidence is robust.
Oral hyaluronic acid supplementation combined with topical HA more efficiently improves corneal epithelial wound healing and DED symptoms than topical HA alone, per a pilot study. Topical HA combined with CoQ10 and vitamin E shows clinical improvements in DED. Hyaluronic acid is a humectant that attracts water and promotes ocular surface hydration and repair.
A double-blind, placebo-controlled RCT (Deinema et al., Ophthalmology 2017; n=60) showed krill oil supplementation for 90 days significantly reduced tear osmolarity and OSDI symptom scores versus placebo, with the krill oil group uniquely achieving significant reductions in the proinflammatory cytokine IL-17A. These benefits were superior to or additive versus fish oil on symptom measures.
Lactoferrin is a natural glycoprotein in healthy tear fluid; low tear lactoferrin correlates with DED severity. Clinical RCTs show oral lactoferrin ameliorates DED symptoms and improves tear film stability by downregulating TNF-α, IL-1, IL-6, and IL-8. Animal studies confirm oral lactoferrin maintains tear secretion in DED models. It is one of ten evidence-supported DED nutrients per a 2024 Frontiers in Pharmacology review.
Multiple RCTs demonstrate that lutein supplementation (typically 20 mg/day) improves TBUT, tear meniscus height, Schirmer test, OSDI, and MMP-9 in DED patients within 3–8 weeks. Lutein inhibits IL-6 secretion in corneal epithelial cells via NF-κB signaling, reducing ocular surface inflammation. It is one of four active ingredients in a validated 8-week DED RCT meeting primary endpoints.
Maqui berry extract is among the best-supported applications, with a pilot trial and a full RCT both showing significantly increased tear fluid production. A randomized, double-blind, placebo-controlled trial in 74 adults found that 60 mg MaquiBright® daily for 4 weeks produced significantly higher tear fluid volume vs. placebo. A further 2022–2023 prospective interventional study confirmed improvement in DED signs and reduction in ocular surface inflammatory markers.
Mucin deficiency on the ocular surface is a recognized driver of dry eye disease (DED), and pharmacological agents that stimulate mucin secretion (mucin secretagogues) are clinically proven treatments. Randomized controlled trials demonstrate that mucin secretagogue eye drops (diquafosol, rebamipide) significantly improve corneal staining, tear breakup time, and symptom scores. Alterations in both cell surface-associated and gel-forming mucins occur in dry-eye-related ocular surface diseases.
Multiple meta-analyses of RCTs confirm that omega-3 supplementation significantly improves dry eye disease (DED) symptoms, tear break-up time (TBUT), Schirmer test scores, and tear osmolarity. A 2023 meta-analysis of 19 RCTs (4,246 patients) found significant benefits especially at higher doses and longer durations. The anti-inflammatory mechanism involves modulating prostaglandin metabolism and enhancing lacrimal gland secretion.
Sea buckthorn oil—rich in omega-7 palmitoleic acid—has been studied in RCTs for dry eye disease. Larmo et al. (J Nutr, 2010) conducted a double-blind, placebo-controlled trial in 100 participants and found oral sea buckthorn oil attenuated tear film osmolarity and reduced dry eye symptoms over 3 months. A further study in Sjögren's syndrome patients reported overall improvement in ocular mucosal symptoms with sea buckthorn supplementation.
Vitamin A palmitate eye gel has been tested clinically for dry eye syndrome and shown to improve tear film stability. Topical retinyl palmitate supports the goblet cells and mucin layer of the ocular surface.
Dexpanthenol has been investigated as an active ingredient in eye drops for dry eye disease (DED). A randomized double-blind placebo-controlled study in 50 dry eye patients showed significant improvement in corneal epithelial permeability and tear film parameters with dexpanthenol-containing artificial tears. A ClinicalTrials.gov-registered trial (NCT06210373) is assessing 5% dexpanthenol eye gel for moderate-to-severe DED.
Saffron's active constituents (crocin, crocetin, safranal) have antioxidant and anti-inflammatory properties studied in ocular diseases. A 2022 systematic review of antioxidants for eye aging noted that saffron extract is a relevant ocular antioxidant that can alleviate symptoms of dry eye disease. Evidence is primarily from mechanistic data and indirect clinical observations rather than dedicated DED-specific RCTs.
Selenium is an antioxidant trace mineral that protects the ocular surface and lacrimal gland from oxidative stress relevant to DED. It is included in validated DED multivitamin formulations showing significant clinical benefit. A 2024 Frontiers in Pharmacology systematic review confirmed selenium as one of ten evidence-supported nutrients for dry eye management.
Reduced SPM levels have been measured in human tear fluid in dry eye disease. An RvE1 stable analog (RX-10045) successfully completed a Phase II human clinical trial for dry eye inflammation, demonstrating reduced corneal staining and symptom scores. Dry eye disease represents the most clinically advanced SPM indication in ophthalmology.
Vitamin A deficiency directly causes xerophthalmia and DED via goblet cell loss and corneal keratinization. Topical and oral vitamin A supplementation reduces dry eye signs and symptoms and promotes goblet cell proliferation, as confirmed in clinical studies. It is recognized as an essential nutrient for ocular surface integrity by major ophthalmic bodies.
Vitamin C is an antioxidant present in tear fluid that neutralizes reactive oxygen species and prevents UV-induced ocular surface damage. It is included in validated DED multivitamin formulations showing significant symptom improvement. Deficiency contributes to oxidative ocular surface damage relevant to DED pathogenesis.
A meta-analysis of 14 studies found serum 25(OH)D3 significantly lower in DED patients versus controls (WMD −5.93; p<0.001). Clinical trials show vitamin D3 supplementation improves TBUT, Schirmer, and OSDI. When combined with lutein, zeaxanthin, and curcumin in an 8-week RCT (n=155), it met primary DED endpoints (p<0.001 both measures).
Vitamin E (tocopherol) is a fat-soluble antioxidant included in validated DED multivitamin formulations showing significant symptom improvement. It has analgesic antioxidant effects in neuropathic ocular pain relevant to DED. Topical vitamin E combined with crosslinked hyaluronic acid and CoQ10 also improves dry eye in clinical studies.
Zeaxanthin co-supplemented with lutein improves tear production, stability, and quality while reducing ocular surface inflammation in DED across multiple RCTs. An 8-week double-blind RCT (n=155) with zeaxanthin 4 mg + lutein + curcumin + vitamin D3 significantly improved Schirmer test and OSDI (p<0.001). A 20-day RCT (n=110) reduced OSDI by ~52%.
Zinc is critical for activating antioxidant enzymes, cellular repair of ocular surface cells, and modulating immune responses in DED. A clinical DED multivitamin study found oral zinc-containing supplements improved intractable dry eye. Topical zinc-hyaluronate improves DED symptoms by reducing corneal receptor excitability, confirmed in published clinical studies.
Eyebright (Euphrasia officinalis) has been used in European herbal medicine since the 14th century for eye ailments including irritation, conjunctivitis, and dry eyes, based on its astringent tannins and iridoid constituents. However, no rigorous clinical RCTs have confirmed efficacy specifically for dry eyes; PeaceHealth and WebMD note the absence of good scientific evidence for its traditional uses.
Volver